Hypertension remains to be a global health burden. Both the American College of Cardiology / American Heart Association (ACC/AHA) and European Society of Cardiology / European Society of Hypertension (ESC/ESH) recognizes the need for out-of-office blood pressure monitoring to identify both white coat hypertension or white coat syndrome, and masked hypertension. While there is no hard evidence to show long-term benefit of treatment of white coat hypertension with hypertension-mediated organ damage (HMOD) and masked hypertension due to methodological issues in studies, there is a recognized increased CV risk in both entities that may need to be addressed.
This e-learning module summarizes the diagnostic approach to masked and white coat hypertension, and reviews the data behind possible management options for these conditions.
Michael John N. Barcelona, MD FPCP FPCC
Internal Medicine – Adult and Interventional Cardiology
Keywords: Hypertension, masked hypertension, white coat syndrome